Taming the gatekeeper: ponatinib dose holds the key Comment

In this issue of Blood, Cortes et al demonstrate that the optimal benefit-to-risk outcome for ponatinib-treated patients with chronic myeloid leukemia (CML) who had failed prior therapy was a starting dose of 45 mg, which was reduced to 15 mg upon attainment of a response.

Automated summary

The study demonstrated that an optimal benefit-to-risk outcome for patients with chronic myeloid leukemia who had failed prior therapy was to start with a dose of 45 mg of ponatinib, which could then be reduced to 15 mg upon attainment of a response.